Pediatric melanoma

Analysis of an international registry

Bruce J. Averbook, Sandra J. Lee, Keith A. Delman, Kenneth W. Gow, Jonathan S. Zager, Vernon K. Sondak, Jane L. Messina, Michael S. Sabel, Mark R. Pittelkow, Phillip M. Ecker, Svetomir N. Markovic, Susan M. Swetter, Sancy A. Leachman, Alessandro Testori, Clara Curiel-Lewandrowski, Ronald S. Go, Drazen M. Jukic, John M. Kirkwood

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background The management of pediatric melanoma (PM) has largely been extrapolated from adult data. However, the behavior of PM appears to differ from its adult counterparts. Therefore, an international PM registry was created and analyzed. Methods Twelve institutions contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008. Results Overall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow-up data. The mean age of the patients was 16 years (range 1 year-21 years). The 10-year OS rate, 80.6%, tended to vary by patient age: 100% for those aged birth to 10 years, 69.7% for those aged > 10 years to 15 years, and 79.5% for those aged > 15 years to 20 years (P =.147). Patients with melanomas measuring ≤ 1 mm had a favorable prognosis (10-year OS rate of 97%), whereas survival was lower but similar for patients with melanomas measuring > 1 mm to 2 mm, > 2 mm to 4 mm, and > 4 mm (70%, 78%, and 80%, respectively; P =.0077). Ulceration and lymph node metastasis were found to be correlated with worse survival (P =.022 and P =.017, respectively). The 10-year OS rate was 94.1% for patients with American Joint Committee on Cancer stage I disease, 79.6% for those with stage II disease, and 77.1% for patients with stage III disease (P 10 years. Further analyses are needed to probe for potential biological and behavioral differences in pediatric versus adult melanoma.

Original languageEnglish
Pages (from-to)4012-4019
Number of pages8
JournalCancer
Volume119
Issue number22
DOIs
Publication statusPublished - Nov 15 2013

Fingerprint

Registries
Melanoma
Pediatrics
Survival Rate
Survival
Lymph Nodes
Parturition
Neoplasm Metastasis
Neoplasms

Keywords

  • melanoma
  • mitotic rate
  • pediatric
  • sentinel lymph node biopsy
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Averbook, B. J., Lee, S. J., Delman, K. A., Gow, K. W., Zager, J. S., Sondak, V. K., ... Kirkwood, J. M. (2013). Pediatric melanoma: Analysis of an international registry. Cancer, 119(22), 4012-4019. https://doi.org/10.1002/cncr.28289

Pediatric melanoma : Analysis of an international registry. / Averbook, Bruce J.; Lee, Sandra J.; Delman, Keith A.; Gow, Kenneth W.; Zager, Jonathan S.; Sondak, Vernon K.; Messina, Jane L.; Sabel, Michael S.; Pittelkow, Mark R.; Ecker, Phillip M.; Markovic, Svetomir N.; Swetter, Susan M.; Leachman, Sancy A.; Testori, Alessandro; Curiel-Lewandrowski, Clara; Go, Ronald S.; Jukic, Drazen M.; Kirkwood, John M.

In: Cancer, Vol. 119, No. 22, 15.11.2013, p. 4012-4019.

Research output: Contribution to journalArticle

Averbook, BJ, Lee, SJ, Delman, KA, Gow, KW, Zager, JS, Sondak, VK, Messina, JL, Sabel, MS, Pittelkow, MR, Ecker, PM, Markovic, SN, Swetter, SM, Leachman, SA, Testori, A, Curiel-Lewandrowski, C, Go, RS, Jukic, DM & Kirkwood, JM 2013, 'Pediatric melanoma: Analysis of an international registry', Cancer, vol. 119, no. 22, pp. 4012-4019. https://doi.org/10.1002/cncr.28289
Averbook BJ, Lee SJ, Delman KA, Gow KW, Zager JS, Sondak VK et al. Pediatric melanoma: Analysis of an international registry. Cancer. 2013 Nov 15;119(22):4012-4019. https://doi.org/10.1002/cncr.28289
Averbook, Bruce J. ; Lee, Sandra J. ; Delman, Keith A. ; Gow, Kenneth W. ; Zager, Jonathan S. ; Sondak, Vernon K. ; Messina, Jane L. ; Sabel, Michael S. ; Pittelkow, Mark R. ; Ecker, Phillip M. ; Markovic, Svetomir N. ; Swetter, Susan M. ; Leachman, Sancy A. ; Testori, Alessandro ; Curiel-Lewandrowski, Clara ; Go, Ronald S. ; Jukic, Drazen M. ; Kirkwood, John M. / Pediatric melanoma : Analysis of an international registry. In: Cancer. 2013 ; Vol. 119, No. 22. pp. 4012-4019.
@article{4614e7a7246648de81d95157e1a6c644,
title = "Pediatric melanoma: Analysis of an international registry",
abstract = "Background The management of pediatric melanoma (PM) has largely been extrapolated from adult data. However, the behavior of PM appears to differ from its adult counterparts. Therefore, an international PM registry was created and analyzed. Methods Twelve institutions contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008. Results Overall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow-up data. The mean age of the patients was 16 years (range 1 year-21 years). The 10-year OS rate, 80.6{\%}, tended to vary by patient age: 100{\%} for those aged birth to 10 years, 69.7{\%} for those aged > 10 years to 15 years, and 79.5{\%} for those aged > 15 years to 20 years (P =.147). Patients with melanomas measuring ≤ 1 mm had a favorable prognosis (10-year OS rate of 97{\%}), whereas survival was lower but similar for patients with melanomas measuring > 1 mm to 2 mm, > 2 mm to 4 mm, and > 4 mm (70{\%}, 78{\%}, and 80{\%}, respectively; P =.0077). Ulceration and lymph node metastasis were found to be correlated with worse survival (P =.022 and P =.017, respectively). The 10-year OS rate was 94.1{\%} for patients with American Joint Committee on Cancer stage I disease, 79.6{\%} for those with stage II disease, and 77.1{\%} for patients with stage III disease (P 10 years. Further analyses are needed to probe for potential biological and behavioral differences in pediatric versus adult melanoma.",
keywords = "melanoma, mitotic rate, pediatric, sentinel lymph node biopsy, survival",
author = "Averbook, {Bruce J.} and Lee, {Sandra J.} and Delman, {Keith A.} and Gow, {Kenneth W.} and Zager, {Jonathan S.} and Sondak, {Vernon K.} and Messina, {Jane L.} and Sabel, {Michael S.} and Pittelkow, {Mark R.} and Ecker, {Phillip M.} and Markovic, {Svetomir N.} and Swetter, {Susan M.} and Leachman, {Sancy A.} and Alessandro Testori and Clara Curiel-Lewandrowski and Go, {Ronald S.} and Jukic, {Drazen M.} and Kirkwood, {John M.}",
year = "2013",
month = "11",
day = "15",
doi = "10.1002/cncr.28289",
language = "English",
volume = "119",
pages = "4012--4019",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "22",

}

TY - JOUR

T1 - Pediatric melanoma

T2 - Analysis of an international registry

AU - Averbook, Bruce J.

AU - Lee, Sandra J.

AU - Delman, Keith A.

AU - Gow, Kenneth W.

AU - Zager, Jonathan S.

AU - Sondak, Vernon K.

AU - Messina, Jane L.

AU - Sabel, Michael S.

AU - Pittelkow, Mark R.

AU - Ecker, Phillip M.

AU - Markovic, Svetomir N.

AU - Swetter, Susan M.

AU - Leachman, Sancy A.

AU - Testori, Alessandro

AU - Curiel-Lewandrowski, Clara

AU - Go, Ronald S.

AU - Jukic, Drazen M.

AU - Kirkwood, John M.

PY - 2013/11/15

Y1 - 2013/11/15

N2 - Background The management of pediatric melanoma (PM) has largely been extrapolated from adult data. However, the behavior of PM appears to differ from its adult counterparts. Therefore, an international PM registry was created and analyzed. Methods Twelve institutions contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008. Results Overall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow-up data. The mean age of the patients was 16 years (range 1 year-21 years). The 10-year OS rate, 80.6%, tended to vary by patient age: 100% for those aged birth to 10 years, 69.7% for those aged > 10 years to 15 years, and 79.5% for those aged > 15 years to 20 years (P =.147). Patients with melanomas measuring ≤ 1 mm had a favorable prognosis (10-year OS rate of 97%), whereas survival was lower but similar for patients with melanomas measuring > 1 mm to 2 mm, > 2 mm to 4 mm, and > 4 mm (70%, 78%, and 80%, respectively; P =.0077). Ulceration and lymph node metastasis were found to be correlated with worse survival (P =.022 and P =.017, respectively). The 10-year OS rate was 94.1% for patients with American Joint Committee on Cancer stage I disease, 79.6% for those with stage II disease, and 77.1% for patients with stage III disease (P 10 years. Further analyses are needed to probe for potential biological and behavioral differences in pediatric versus adult melanoma.

AB - Background The management of pediatric melanoma (PM) has largely been extrapolated from adult data. However, the behavior of PM appears to differ from its adult counterparts. Therefore, an international PM registry was created and analyzed. Methods Twelve institutions contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008. Results Overall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow-up data. The mean age of the patients was 16 years (range 1 year-21 years). The 10-year OS rate, 80.6%, tended to vary by patient age: 100% for those aged birth to 10 years, 69.7% for those aged > 10 years to 15 years, and 79.5% for those aged > 15 years to 20 years (P =.147). Patients with melanomas measuring ≤ 1 mm had a favorable prognosis (10-year OS rate of 97%), whereas survival was lower but similar for patients with melanomas measuring > 1 mm to 2 mm, > 2 mm to 4 mm, and > 4 mm (70%, 78%, and 80%, respectively; P =.0077). Ulceration and lymph node metastasis were found to be correlated with worse survival (P =.022 and P =.017, respectively). The 10-year OS rate was 94.1% for patients with American Joint Committee on Cancer stage I disease, 79.6% for those with stage II disease, and 77.1% for patients with stage III disease (P 10 years. Further analyses are needed to probe for potential biological and behavioral differences in pediatric versus adult melanoma.

KW - melanoma

KW - mitotic rate

KW - pediatric

KW - sentinel lymph node biopsy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84887099210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887099210&partnerID=8YFLogxK

U2 - 10.1002/cncr.28289

DO - 10.1002/cncr.28289

M3 - Article

VL - 119

SP - 4012

EP - 4019

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 22

ER -